Our Services
Medical Information
Helpful Resources
Published on: 9/14/2026
Yes, duloxetine (Cymbalta) can cause a withdrawal (discontinuation) syndrome and, less commonly, serotonin syndrome, but risk depends on dose, duration, how quickly it is stopped, and what else you take, so there are important details to consider below. Stopping abruptly may trigger dizziness, "brain zaps," nausea, headache, irritability, insomnia, sweating, and flu-like symptoms, often starting within a few days and usually easing over 1 to 2 weeks, though some people experience longer or more severe symptoms. Serotonin syndrome is rare but can be life-threatening, and it is most likely when Cymbalta is combined with other serotonergic agents such as SSRIs, MAOIs, triptans, tramadol, linezolid, or St. John's wort, producing agitation, confusion, tremor, muscle rigidity, fast heart rate, high fever, or seizures that require emergency care. Slow, clinician-guided tapering rather than sudden discontinuation substantially reduces withdrawal risk, and the full guidance below explains warning signs that mean you should seek help immediately.
Because withdrawal symptoms and early serotonin syndrome can look similar to anxiety, flu, or a relapse of depression, sorting out what is actually happening matters for your safety and your next step. A free, instant, online symptom check can help you organize your symptoms, timeline, and medications, flag features that need urgent evaluation, and prepare you for a
Cymbalta (duloxetine) is a commonly prescribed antidepressant in the class of serotonin-norepinephrine reuptake inhibitors (SNRIs). It’s FDA-approved for major depressive disorder, generalized anxiety disorder, diabetic neuropathy, fibromyalgia and chronic musculoskeletal pain. Like all SNRIs, cymbalta affects levels of serotonin and norepinephrine in the brain to help regulate mood and pain.
While many people benefit from cymbalta, it’s important to understand the risks associated with stopping it and with drug interactions that can trigger serotonin syndrome. This guide explains:
Cymbalta adjusts your brain chemistry over weeks to months. If you stop abruptly or taper too quickly, your brain may not have time to rebalance, leading to uncomfortable symptoms known as a discontinuation syndrome.
Most people experience mild to moderate symptoms. In rare cases, symptoms can be severe:
Serotonin syndrome is a potentially life-threatening reaction caused by too much serotonin in the brain and body. It can occur when you increase your dose of cymbalta too quickly or combine it with other medications or supplements that boost serotonin.
Serotonin syndrome can develop within hours of a dose change or new medication. Watch for a combination of:
Cognitive/Behavioral
Autonomic (involuntary function)
Neuromuscular
Call 911 or go to the nearest emergency department if you experience:
Q: Is cymbalta addictive?
A: Cymbalta does not produce cravings or euphoria like narcotics. However, your body can become accustomed to its effects, so stopping abruptly can trigger withdrawal symptoms.
Q: How long do withdrawal symptoms last?
A: Mild symptoms may resolve in 1–3 weeks. More persistent or severe symptoms can last a month or longer, depending on how slowly you taper.
Q: Can psychotherapy help during a taper?
A: Yes. Cognitive-behavioral therapy (CBT) and other talk therapies can ease anxiety, insomnia or mood swings during withdrawal.
Always consult your doctor or mental health professional before making changes to your medication. Speak up if you experience:
If you’re ever unsure whether your symptoms are serious, err on the side of caution. You might also try a free, online symptom check, using the doctor approved Ubie Symptom Checker to get guidance on whether to seek immediate care.
—
This information is intended to help you understand the risks of cymbalta withdrawal and serotonin syndrome. It does not replace personalized medical advice. If you experience life-threatening symptoms or have concerns about your treatment, please speak to a doctor right away.
(References)
* Gelener P, Gorgulu U, Kutlu G, Ucler S, Inan LE. Serotonin syndrome due to duloxetine. Clin Neuropharmacol. 2011 May-Jun;34(3):127-8. doi: 10.1097/WNF.0b013e31821b3aa0. PMID: 21586918.
* Domperidone. 2006. PMID: 30000430.
* Fava GA, Benasi G, Lucente M, Offidani E, Cosci F, Guidi J. Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review. Psychother Psychosom. 2018;87(4):195-203. doi: 10.1159/000491524. Epub 2018 Jul 17. PMID: 30016772.
* Shelton RC. Serotonin and Norepinephrine Reuptake Inhibitors. Handb Exp Pharmacol. 2019;250:145-180. doi: 10.1007/164_2018_164. PMID: 30838456.
* Birkinshaw H, Friedrich CM, Cole P, Eccleston C, Serfaty M, Stewart G, White S, Moore RA, Phillippo D, Pincus T. Antidepressants for pain management in adults with chronic pain: a network meta-analysis. Cochrane Database Syst Rev. 2023 May 10;5(5):CD014682. doi: 10.1002/14651858.CD014682.pub2. Epub 2023 May 10. PMID: 37160297; PMCID: PMC10169288.
* Li L, Mi Q. Serotonin Syndrome From Duloxetine Monotherapy: A Case Report. Cureus. 2023 Jun;15(6):e40933. doi: 10.7759/cureus.40933. Epub 2023 Jun 25. PMID: 37496538; PMCID: PMC10368303.
* Yang P, Chen H, Wang T, Su H, Li J, He Y, Su S. Electroacupuncture promotes synaptic plasticity in rats with chronic inflammatory pain-related depression by upregulating BDNF/TrkB/CREB signaling pathway. Brain Behav. 2023 Dec;13(12):e3310. doi: 10.1002/brb3.3310. Epub 2023 Nov 10. PMID: 37948105; PMCID: PMC10726860.
* Birkinshaw H, Friedrich C, Cole P, Eccleston C, Serfaty M, Stewart G, White S, Moore A, Phillippo D, Pincus T. Antidepressants for pain management in adults with chronic pain: a network meta-analysis. Health Technol Assess. 2024 Oct;28(62):1-155. doi: 10.3310/MKRT2948. PMID: 39367772; PMCID: PMC11474957.
* Liu D, Li N, Liu L, Qiu L, Zhou Z, Wu J. Uncovering safety signals of duloxetine: Real-world evidence from the FAERS database. J Affect Disord. 2025 Nov 1;388:119517. doi: 10.1016/j.jad.2025.119517. Epub 2025 May 27. PMID: 40441644.
* Mohseni M, Ghaderzadeh R, Bakhtiari K, Zamanirafe M, Doostizadeh M, Tabatabaeii Mohammadi A, Amini K, Mehrpooya M. Tolerability and Efficacy of Duloxetine Compared to Amitriptyline in Women With Chronic Pelvic Pain Syndrome: Findings From a Clinical Trial. Low Urin Tract Symptoms. 2025 Jul;17(4):e70023. doi: 10.1111/luts.70023. PMID: 40717304.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.